8-K Announcements
6Material company update
May 19, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Apr 27, 2026·SEC
Eton Pharmaceuticals, Inc.(ETON)Earnings, Financials & Key Ratios
ETON•NASDAQ
Price updated Jun 19, 2026
AboutEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Show more
- Revenue$80M+104.9%
- EBITDA$4M+383.7%
- Net Income-$5M-20.4%
- EPS (Diluted)-0.17-13.3%
- Gross Margin53.46%-10.9%
- EBITDA Margin5.15%+238.4%
- Operating Margin0.09%+101.4%
- Net Margin-5.75%+41.3%
- ROE-18.19%+5.1%
ETON Key Insights
Eton Pharmaceuticals, Inc. (ETON) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 30.3%
- ✓Momentum leader: RS Rating 93 (top 7%)
- ✓Strong 5Y sales CAGR of 359.6%
✗Weaknesses
- ✗Expensive at 33.4x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ETON posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ETON Price & Volume
Eton Pharmaceuticals, Inc. (ETON) stock price & volume — 10-year historical chart
Loading chart...
ETON Growth Metrics
Eton Pharmaceuticals, Inc. (ETON) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years359.57%
3 Years55.53%
TTM79.89%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM67.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM65.41%
Return on Capital
10 Years-44.88%
5 Years-12.1%
3 Years-4.7%
Last Year0.13%
ETON Recent Earnings
Eton Pharmaceuticals, Inc. (ETON) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.05-50.0%
$0.10
Rev
$24M+8.8%
$22M
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.05-58.3%
$0.12
Rev
$21M+6.5%
$20M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.07-143.8%
$0.16
Rev
$22M+9.7%
$20M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.10-900.0%
$0.01
Rev
$19M-7.6%
$20M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.05vs $0.10-50.0% | $24Mvs $22M+8.8% |
| Q2 2026 | Mar 19, 2026 | $0.05vs $0.12-58.3% | $21Mvs $20M+6.5% |
| Q4 2025 | Nov 6, 2025 | $0.07vs $0.16-143.8% | $22Mvs $20M+9.7% |
| Q3 2025 | Aug 7, 2025 | $0.10vs $0.01-900.0% | $19Mvs $20M-7.6% |
Based on last 12 quarters of dataView full earnings history →
ETON Peer Comparison
Eton Pharmaceuticals, Inc. (ETON) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 AVDL | 2.1B | 21.64 | -42.43 | 5.05% | -0.11% | -0.33% | 0.02 | |
 TLRY | 551.15M | 4.73 | -0.14 | 4.84% | -252.55% | -136.55% | 0.22 | |
 MNPR | 451.99M | 67.47 | -36.47 | -12.84% | 0.00 | |||
 KALA | 79.17M | 3.61 | -1.09 | -13.36% | ||||
 SLRX | 697.79K | 0.74 | -0.01 | -117.81% | 0.15 | |||
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 |
Compare ETON vs Peers
Eton Pharmaceuticals, Inc. (ETON) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ETON Income Statement
Eton Pharmaceuticals, Inc. (ETON) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 959K | 39K | 21.83M | 21.25M | 31.64M | 39.01M | 79.95M | 86.93M |
Revenue Growth % | - | - | - | -95.93% | 55879.49% | -2.66% | 48.9% | 23.29% | 104.94% | 79.89% |
Cost of Goods Sold | 13K | 63K | 453K | 286K | 2.62M | 6.93M | 10.58M | 15.6M | 37.21M | 39.32M |
COGS % of Revenue | - | - | 47.24% | 733.33% | 12.01% | 32.62% | 33.44% | 39.99% | 46.54% | - |
Gross Profit | -13K▲ 0% | -63K▼ 384.6% | 506K▲ 903.2% | -247K▼ 148.8% | 19.21M▲ 7876.9% | 14.32M▼ 25.5% | 21.06M▲ 47.1% | 23.41M▲ 11.2% | 42.74M▲ 82.6% | 47.61M▲ 0% |
Gross Margin % | - | - | 52.76% | -633.33% | 87.99% | 67.38% | 66.56% | 60.01% | 53.46% | 54.77% |
Gross Profit Growth % | - | -384.62% | 903.17% | -148.81% | 7876.92% | -25.46% | 47.09% | 11.16% | 82.56% | - |
Operating Expenses | 7.14M | 10.32M | 19.11M | 26.86M | 20.7M | 22.58M | 22.25M | 26.01M | 42.67M | 45.57M |
OpEx % of Revenue | - | - | 1992.39% | 68882.05% | 94.83% | 106.24% | 70.33% | 66.67% | 53.37% | - |
Selling, General & Admin | 3.21M | 4.69M | 7.55M | 12.76M | 14.47M | 18.58M | 18.93M | 22.75M | 35.82M | 37.09M |
SG&A % of Revenue | - | - | 787.49% | 32717.95% | 66.27% | 87.44% | 59.83% | 58.32% | 44.8% | - |
Research & Development | 3.93M | 5.63M | 11.55M | 14.1M | 6.24M | 4M | 3.32M | 3.25M | 7.76M | 8.48M |
R&D % of Revenue | - | - | 1204.9% | 36164.1% | 28.56% | 18.8% | 10.5% | 8.34% | 9.71% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -916K | 0 |
Operating Income | -7.15M▲ 0% | -10.32M▼ 44.3% | -18.6M▼ 80.2% | -27.11M▼ 45.8% | -1.5M▲ 94.5% | -8.26M▼ 452.5% | -1.19M▲ 85.6% | -2.6M▼ 117.9% | 72K▲ 102.8% | 2.04M▲ 0% |
Operating Margin % | - | - | -1939.62% | -69515.38% | -6.85% | -38.87% | -3.77% | -6.66% | 0.09% | 2.35% |
Operating Income Growth % | - | -44.35% | -80.22% | -45.75% | 94.49% | -452.51% | 85.57% | -117.87% | 102.77% | - |
EBITDA | -7.14M | -10.26M | -18.15M | -26.46M | -1.03M | -6.49M | -291K | -1.45M | 4.12M | 5.07M |
EBITDA Margin % | - | - | -1893.01% | -67846.15% | -4.73% | -30.52% | -0.92% | -3.72% | 5.15% | 5.83% |
EBITDA Growth % | - | -43.73% | -76.97% | -45.75% | 96.1% | -527.88% | 95.51% | -398.63% | 383.67% | 1582.75% |
D&A (Non-Cash Add-back) | 13K | 63K | 447K | 651K | 462K | 1.77M | 901K | 1.15M | 4.04M | 3.03M |
EBIT | -7.16M | -10.32M | -18.6M | -27.11M | -1.5M | -8.26M | -1.19M | -2.6M | 72K | 2.67M |
Net Interest Income | 0 | 0 | 281K | -889K | 0 | 0 | 0 | -2M | -4.78M | -2.78M |
Interest Income | 52.5K | 164K | 281K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 889K | 0 | 0 | 0 | 2M | 4.78M | 2.78M |
Other Income/Expense | -6K | -2.42M | 281K | -859K | -460K | -761K | 503K | -1.21M | -4.63M | -3.53M |
Pretax Income | -7.16M▲ 0% | -12.74M▼ 78.0% | -18.32M▼ 43.8% | -27.97M▼ 52.7% | -1.96M▲ 93.0% | -9.02M▼ 361.4% | -689K▲ 92.4% | -3.81M▼ 452.7% | -4.56M▼ 19.7% | -1.49M▲ 0% |
Pretax Margin % | - | - | -1910.32% | -71717.95% | -8.95% | -42.45% | -2.18% | -9.76% | -5.7% | -1.71% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 247K | 15K | 43K | -11K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | -35.85% | -0.39% | -0.94% | 0.74% |
Net Income | -7.16M▲ 0% | -12.74M▼ 78.0% | -18.32M▼ 43.8% | -27.97M▼ 52.7% | -1.96M▲ 93.0% | -9.02M▼ 361.4% | -936K▲ 89.6% | -3.82M▼ 308.4% | -4.6M▼ 20.4% | -1.48M▲ 0% |
Net Margin % | - | - | -1910.32% | -71717.95% | -8.95% | -42.45% | -2.96% | -9.8% | -5.75% | -1.7% |
Net Income Growth % | - | -78.03% | -43.8% | -52.67% | 93.01% | -361.43% | 89.62% | -308.44% | -20.35% | 67.82% |
Net Income (Continuing) | -7.16M | -12.74M | -18.32M | -27.97M | -1.96M | -9.02M | -936K | -3.82M | -4.6M | -1.48M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.41▲ 0% | -1.99▼ 385.4% | -1.02▲ 48.7% | -1.33▼ 30.4% | -0.08▲ 94.2% | -0.36▼ 363.9% | -0.04▲ 89.9% | -0.15▼ 311.0% | -0.17▼ 13.3% | -0.05▲ 0% |
EPS Growth % | - | -385.37% | 48.74% | -30.39% | 94.17% | -363.92% | 89.86% | -310.96% | -13.33% | 65.41% |
EPS (Basic) | -0.41 | -1.99 | -1.02 | -1.33 | -0.08 | -0.36 | -0.04 | -0.15 | -0.17 | - |
Diluted Shares Outstanding | 17.46M | 6.42M | 17.76M | 21.01M | 25.21M | 25.15M | 25.65M | 25.89M | 26.91M | 31.55M |
Basic Shares Outstanding | 17.46M | 6.42M | 17.76M | 21.01M | 25.21M | 25.15M | 25.64M | 25.89M | 26.91M | 27.29M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ETON Balance Sheet
Eton Pharmaceuticals, Inc. (ETON) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 13.29M | 27.5M | 15.01M | 24.7M | 23.6M | 20M | 26.84M | 41.02M | 60.58M | 53.24M |
Cash & Short-Term Investments | 13.16M | 26.73M | 12.07M | 21.3M | 14.41M | 16.3M | 21.39M | 14.94M | 25.94M | 19.66M |
Cash Only | 13.16M | 26.73M | 12.07M | 21.3M | 14.41M | 16.3M | 21.39M | 14.94M | 25.94M | 19.66M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 473K | 48K | 5.47M | 1.85M | 3.41M | 5.36M | 11.76M | 13.41M |
Days Sales Outstanding | - | - | 180.03 | 449.23 | 91.47 | 31.81 | 39.35 | 50.16 | 53.67 | 55.32 |
Inventory | 0 | 0 | 380K | 1.24M | 550K | 557K | 911K | 15.23M | 15.42M | 14.47M |
Days Inventory Outstanding | - | - | 306.18 | 1.59K | 76.53 | 29.32 | 31.43 | 356.39 | 151.25 | 163.68 |
Other Current Assets | 0 | 0 | 1M | 0 | 0 | 1.29M | 0 | 5.49M | 7.46M | 5.71M |
Total Non-Current Assets | 151K | 825K | 2.06M | 1.62M | 3.86M | 5.03M | 4.9M | 35.1M | 31.53M | 44.47M |
Property, Plant & Equipment | 119K | 773K | 1.28M | 1M | 219K | 260K | 150K | 209K | 636K | 673K |
Fixed Asset Turnover | - | - | 0.75x | 0.04x | 99.69x | 81.73x | 210.95x | 186.66x | 125.71x | 153.59x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 725K | 575K | 3.62M | 4.75M | 4.74M | 34.88M | 30.88M | 43.74M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 32K | 52K | 61K | 40K | 21K | 12K | 12K | 12K | 19K | 54K |
Total Assets | 13.44M▲ 0% | 28.33M▲ 110.7% | 17.07M▼ 39.7% | 26.32M▲ 54.2% | 27.46M▲ 4.4% | 25.03M▼ 8.9% | 31.74M▲ 26.8% | 76.12M▲ 139.8% | 92.11M▲ 21.0% | 97.71M▲ 0% |
Asset Turnover | - | - | 0.06x | 0.00x | 0.79x | 0.85x | 1.00x | 0.51x | 0.87x | 0.88x |
Asset Growth % | - | 110.72% | -39.73% | 54.16% | 4.35% | -8.87% | 26.81% | 139.83% | 21.01% | 448.38% |
Total Current Liabilities | 793K | 2.02M | 1.96M | 3.79M | 4.56M | 6.46M | 16.24M | 19.95M | 38.49M | 44.18M |
Accounts Payable | 539K | 1.42M | 575K | 2.34M | 1.77M | 1.77M | 1.85M | 4.17M | 10.98M | 13.48M |
Days Payables Outstanding | 15.13K | 8.23K | 463.3 | 2.99K | 246.86 | 92.97 | 63.75 | 97.5 | 107.67 | 118.04 |
Short-Term Debt | 0 | 0 | 0 | 280K | 1.42M | 1.03M | 5.38M | 0 | 8.79M | 11.81M |
Deferred Revenue (Current) | 0 | 0 | -133K | 0 | 0 | 0 | 0 | 0 | 0 | 330K |
Other Current Liabilities | 0 | 0 | 133K | 0 | 0 | 0 | 0 | 15.74M | 0 | 18.89M |
Current Ratio | 16.76x | 13.59x | 7.65x | 6.51x | 5.18x | 3.10x | 1.65x | 2.06x | 1.57x | 1.21x |
Quick Ratio | 16.76x | 13.59x | 7.45x | 6.18x | 5.06x | 3.01x | 1.60x | 1.29x | 1.17x | 0.88x |
Cash Conversion Cycle | - | - | 22.91 | -957.17 | -78.86 | -31.84 | 7.02 | 309.05 | 97.26 | 100.96 |
Total Non-Current Liabilities | 520K | 1.42M | 4.56M | 6.86M | 5.28M | 5.49M | 22K | 31.75M | 27.47M | 22.92M |
Long-Term Debt | 0 | 0 | 4.54M | 6.76M | 5.26M | 5.38M | 0 | 29.81M | 21.77M | 440K |
Capital Lease Obligations | 0 | 0 | 19K | 99K | 15K | 107K | 22K | 107K | 460K | 492K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 520K | 0 | 0 | 0 | 0 | 0 | 0 | 1.83M | 3.48M | 22.48M |
Total Liabilities | 1.31M | 2.02M | 6.52M | 10.66M | 9.84M | 11.95M | 16.26M | 51.7M | 65.96M | 67.09M |
Total Debt | 0 | 0 | 4.56M | 7.14M | 6.7M | 6.52M | 5.4M | 29.92M | 31.02M | 12.25M |
Net Debt | -13.16M | -26.73M | -7.51M | -14.15M | -7.71M | -9.78M | -15.99M | 14.98M | 5.08M | -7.41M |
Debt / Equity | - | - | 0.43x | 0.46x | 0.38x | 0.50x | 0.35x | 1.22x | 1.19x | 0.40x |
Debt / EBITDA | - | - | - | - | - | - | - | - | 7.54x | 2.42x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 1.23x | -1.46x |
Interest Coverage | - | - | - | -30.50x | - | - | - | -1.30x | 0.02x | 0.96x |
Total Equity | 12.13M▲ 0% | 26.3M▲ 116.8% | 10.55M▼ 59.9% | 15.66M▲ 48.5% | 17.63M▲ 12.6% | 13.08M▼ 25.8% | 15.48M▲ 18.3% | 24.43M▲ 57.8% | 26.15M▲ 7.1% | 30.61M▲ 0% |
Equity Growth % | - | 116.84% | -59.89% | 48.46% | 12.56% | -25.82% | 18.34% | 57.83% | 7.07% | 154.98% |
Book Value per Share | 0.69 | 4.10 | 0.59 | 0.75 | 0.70 | 0.52 | 0.60 | 0.94 | 0.97 | 0.97 |
Total Shareholders' Equity | 12.13M | 26.3M | 10.55M | 15.66M | 17.63M | 13.08M | 15.48M | 24.43M | 26.15M | 30.61M |
Common Stock | 6K | 18K | 18K | 24K | 25K | 25K | 26K | 27K | 27K | 27K |
Retained Earnings | -8.64M | -45.87M | -64.19M | -92.16M | -94.11M | -103.13M | -104.07M | -107.89M | -112.49M | -110.94M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ETON Cash Flow Statement
Eton Pharmaceuticals, Inc. (ETON) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -4.72M | -8.14M | -18.03M | -22.35M | -4.72M | 4.82M | 6.82M | 969K | 10.52M | 15.84M |
Operating CF Margin % | - | - | -1879.67% | -57297.44% | -21.62% | 22.69% | 21.54% | 2.48% | 13.16% | - |
Operating CF Growth % | - | -72.64% | -121.31% | -23.97% | 78.87% | 202.12% | 41.36% | -85.78% | 986.07% | -314.06% |
Net Income | -7.16M | -12.74M | -18.32M | -27.97M | -1.96M | -9.02M | -936K | -3.82M | -4.6M | -1.48M |
Depreciation & Amortization | 13K | 63K | 447K | 651K | 462K | 1.77M | 901K | 1.15M | 4.04M | 4.16M |
Stock-Based Compensation | 2.64M | 1.85M | 1.89M | 2.58M | 3.38M | 4.22M | 3.14M | 3.17M | 5.51M | 4.31M |
Deferred Taxes | 0 | 0 | 0 | 0 | -546K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.29M | 2.58M | 16K | 1.39M | 148K | 189K | 184K | 1.18M | 6.43M | 7.2M |
Working Capital Changes | 623K | 99K | -2.06M | 1.01M | -6.21M | 7.66M | 3.53M | -698K | -859K | 1.64M |
Change in Receivables | 0 | 0 | -473K | 425K | -5.42M | 3.62M | -1.56M | -3.12M | -6.4M | 2.99M |
Change in Inventory | 0 | 0 | -380K | -862K | 692K | -7K | -354K | -1.31M | -5.88M | -4.94M |
Change in Payables | 539K | 413K | -377K | 1.77M | -570K | -8K | 53K | 2.32M | 6.81M | 8.61M |
Cash from Investing | -130K | -236K | -1.85M | -50K | -2.56M | -2.79M | -775K | -40.01M | -333K | -15.41M |
Capital Expenditures | -130K | -236K | -1.1M | -50K | -3.26M | -38K | -775K | -26K | -333K | -15.41M |
CapEx % of Revenue | - | - | 114.29% | 128.21% | 14.93% | 0.18% | 2.45% | 0.07% | 0.42% | 17.72% |
Acquisitions | 0 | 0 | 0 | 0 | 700K | 0 | 0 | -30M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -750K | 0 | 0 | -2.75M | 0 | -9.99M | 0 | 0 |
Cash from Financing | 18M | 21.96M | 5.2M | 31.63M | 391K | -134K | -957K | 32.59M | 815K | 1.81M |
Debt Issued (Net) | 0 | 0 | 4.75M | 2.48M | -150K | -385K | -1.16M | 24.15M | 0 | 0 |
Equity Issued (Net) | 0 | 22.8M | 0 | 28.78M | 541K | 0 | 0 | 8.19M | 598K | 1.81M |
Dividends Paid | 0 | -1.05M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 18M | 205K | 453K | 367K | 0 | 251K | 198K | 248K | 217K | 0 |
Net Change in Cash | 13.16M▲ 0% | 13.58M▲ 3.2% | -14.67M▼ 208.0% | 9.23M▲ 162.9% | -6.89M▼ 174.6% | 1.9M▲ 127.6% | 5.08M▲ 167.7% | -6.45M▼ 226.9% | 11.01M▲ 270.6% | 2.24M▲ 0% |
Free Cash Flow | -4.85M▲ 0% | -8.38M▼ 72.9% | -19.87M▼ 137.1% | -22.4M▼ 12.7% | -7.98M▲ 64.4% | 2.03M▲ 125.5% | 6.04M▲ 197.1% | 943K▼ 84.4% | 10.19M▲ 980.7% | 15.43M▲ 0% |
FCF Margin % | - | - | -2072.16% | -57425.64% | -36.55% | 9.57% | 19.09% | 2.42% | 12.75% | 17.75% |
FCF Growth % | - | -72.88% | -137.11% | -12.7% | 64.37% | 125.48% | 197.1% | -84.39% | 980.7% | 179.55% |
FCF per Share | -0.28 | -1.31 | -1.12 | -1.07 | -0.32 | 0.08 | 0.24 | 0.04 | 0.38 | 0.49 |
FCF Conversion (FCF/Net Income) | 0.66x | 0.64x | 0.98x | 0.80x | 2.41x | -0.53x | -7.28x | -0.25x | -2.29x | -10.46x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 730K | 842K | 665K | 0 | 2.68M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 247K | 82K | 0 | 110K |
ETON Key Ratios
Eton Pharmaceuticals, Inc. (ETON) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -66.3% | -99.42% | -213.41% | -11.74% | -58.75% | -6.56% | -19.16% | -18.19% | -5.68% |
Return on Invested Capital (ROIC) | - | -1068.61% | -893.18% | -19.62% | -93.75% | -64.13% | -10.01% | 0.15% | 11.96% |
Gross Margin | - | 52.76% | -633.33% | 87.99% | 67.38% | 66.56% | 60.01% | 53.46% | 54.77% |
Net Margin | - | -1910.32% | -71717.95% | -8.95% | -42.45% | -2.96% | -9.8% | -5.75% | -1.7% |
Debt / Equity | - | 0.43x | 0.46x | 0.38x | 0.50x | 0.35x | 1.22x | 1.19x | 0.40x |
Interest Coverage | - | - | -30.50x | - | - | - | -1.30x | 0.02x | 0.96x |
FCF Conversion | 0.64x | 0.98x | 0.80x | 2.41x | -0.53x | -7.28x | -0.25x | -2.29x | -10.46x |
Revenue Growth | - | - | -95.93% | 55879.49% | -2.66% | 48.9% | 23.29% | 104.94% | 79.89% |
Related:ETON Dividend History·ETON Revenue History·ETON Price History·ETON P/E History·ETON Financial Ratios·ETON Institutional Holders
ETON SEC Filings & Documents
Eton Pharmaceuticals, Inc. (ETON) SEC filings — annual & quarterly reports (10-K, 10-Q)
ETON Frequently Asked Questions
Eton Pharmaceuticals, Inc. (ETON) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Eton Pharmaceuticals, Inc. (ETON) reported $86.9M in revenue for fiscal year 2025.
Eton Pharmaceuticals, Inc. (ETON) grew revenue by 104.9% over the past year. This is strong growth.
Eton Pharmaceuticals, Inc. (ETON) reported a net loss of $1.5M for fiscal year 2025.
Dividend & Returns
Eton Pharmaceuticals, Inc. (ETON) has a return on equity (ROE) of -18.2%. Negative ROE indicates the company is unprofitable.
Eton Pharmaceuticals, Inc. (ETON) generated $15.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.